Viewing Study NCT01660451


Ignite Creation Date: 2025-12-24 @ 11:56 PM
Ignite Modification Date: 2025-12-25 @ 9:53 PM
Study NCT ID: NCT01660451
Status: COMPLETED
Last Update Posted: 2024-07-17
First Post: 2012-08-06
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Sponsor: Bayer
Organization: